133 related articles for article (PubMed ID: 22738254)
41. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
42. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.
El Hussein S; Medeiros LJ; Lyapichev KA; Fang H; Jelloul FZ; Fiskus W; Chen J; Wei P; Schlette E; Xu J; Li S; Kanagal-Shamanna R; Yang H; Tang Z; Thakral B; Loghavi S; Jain N; Thompson PA; Ferrajoli A; Wierda WG; Jabbour E; Patel KP; Dabaja BS; Bhalla KN; Khoury JD
Pathology; 2023 Jun; 55(4):514-524. PubMed ID: 36933995
[TBL] [Abstract][Full Text] [Related]
43. Comparison of genetic aberrations in CD10+ diffused large B-cell lymphoma and follicular lymphoma by comparative genomic hybridization and tissue-fluorescence in situ hybridization.
Zhang X; Karnan S; Tagawa H; Suzuki R; Tsuzuki S; Hosokawa Y; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2004 Oct; 95(10):809-14. PubMed ID: 15504248
[TBL] [Abstract][Full Text] [Related]
44. Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses.
Maeshima AM; Omatsu M; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2008 Sep; 99(9):1760-8. PubMed ID: 18549405
[TBL] [Abstract][Full Text] [Related]
45. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
46. Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid--a study of 21 cases.
Knief J; Gebauer N; Bernard V; Schemme J; Reddemann K; Gebauer J; Rades D; Brabant G; Lehnert H; Feller AC; Thorns C
J Clin Endocrinol Metab; 2015 Feb; 100(2):754-62. PubMed ID: 25423572
[TBL] [Abstract][Full Text] [Related]
47. Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.
Carreras J; Yukie Kikuti Y; Miyaoka M; Hiraiwa S; Tomita S; Ikoma H; Kondo Y; Shiraiwa S; Ando K; Sato S; Suzuki Y; Miura I; Roncador G; Nakamura N
Am J Surg Pathol; 2018 Jul; 42(7):936-950. PubMed ID: 29738359
[TBL] [Abstract][Full Text] [Related]
48. The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.
Xu H; Duan N; Wang Y; Sun N; Ge S; Li H; Jing X; Liang K; Zhang X; Liu L; Xue C; Zhang C
Pathology; 2020 Feb; 52(2):206-212. PubMed ID: 31883669
[TBL] [Abstract][Full Text] [Related]
49. Clinical features of diffuse large B-cell lymphoma with polyploidy.
Shimono J; Miyoshi H; Seto M; Teshima T; Ohshima K
Pathol Int; 2017 Jan; 67(1):17-23. PubMed ID: 27868293
[TBL] [Abstract][Full Text] [Related]
50. Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.
Morton LM; Cerhan JR; Hartge P; Vasef MA; Neppalli VT; Natkunam Y; Dogan A; Dave BJ; Jain S; Levy R; Lossos IS; Cozen W; Davis S; Schenk MJ; Maurer MJ; Lynch CF; Rothman N; Chatterjee N; Yu K; Staudt LM; Weisenburger DD; Wang SS
Int J Mol Epidemiol Genet; 2011 Aug; 2(3):245-52. PubMed ID: 21915363
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of miR-155 and miR-21 in tumor and stroma cells in diffuse large B-cell lymphoma.
Munch-Petersen HD; Ralfkiaer U; Sjö LD; Hother C; Asmar F; Nielsen BS; Brown P; Ralfkiaer E; Grønbæk K
Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):188-95. PubMed ID: 25265435
[TBL] [Abstract][Full Text] [Related]
52. Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries.
Naresh KN; Ibrahim HA; Lazzi S; Rince P; Onorati M; Ambrosio MR; Bilhou-Nabera C; Amen F; Reid A; Mawanda M; Calbi V; Ogwang M; Rogena E; Byakika B; Sayed S; Moshi E; Mwakigonja A; Raphael M; Magrath I; Leoncini L
Br J Haematol; 2011 Sep; 154(6):770-6. PubMed ID: 21718280
[TBL] [Abstract][Full Text] [Related]
53. Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.
Quentmeier H; Drexler HG; Hauer V; MacLeod RA; Pommerenke C; Uphoff CC; Zaborski M; Berglund M; Enblad G; Amini RM
PLoS One; 2016; 11(12):e0167599. PubMed ID: 27907212
[TBL] [Abstract][Full Text] [Related]
54. Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus.
Vela-Chávez T; Adam P; Kremer M; Bink K; Bacon CM; Menon G; Ferry JA; Fend F; Jaffe ES; Quintanilla-Martínez L
Leuk Lymphoma; 2011 Mar; 52(3):458-66. PubMed ID: 21281227
[TBL] [Abstract][Full Text] [Related]
55. Incidence and clinical significance of aberrant T-cell marker expression on diffuse large B-cell lymphoma cells.
Suzuki Y; Yoshida T; Wang G; Aoki T; Katayama T; Miyamoto S; Miyazaki K; Iwabuchi K; Danbara M; Nakayama M; Horie R; Nakamine H; Sato Y; Nakamura N; Niitsu N
Acta Haematol; 2013; 130(4):230-7. PubMed ID: 23816831
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathological analysis of polyploid diffuse large B-cell lymphoma.
Shimono J; Miyoshi H; Kiyasu J; Kamimura T; Eto T; Miyagishima T; Nagafuji K; Seto M; Teshima T; Ohshima K
PLoS One; 2018; 13(4):e0194525. PubMed ID: 29641580
[TBL] [Abstract][Full Text] [Related]
57. Clinical pathology of primary central nervous system lymphoma in HIV-positive patients-a 41 Chinese patients retrospective study.
Chen J; Sun L; Dai Y; Zhang L; Yang K; Han X; Ding X; Gao H; Zhou X; Wang P
Ann Diagn Pathol; 2023 Apr; 63():152108. PubMed ID: 36638601
[TBL] [Abstract][Full Text] [Related]
58. Toll-like receptor 4-induced inflammatory responses contribute to the tumor-associated macrophages formation and infiltration in patients with diffuse large B-cell lymphoma.
Wang X; Li X; Zhang X; Zang L; Yang H; Zhao W; Zhao H; Li Q; Xia B; Yu Y; Wang Y; Zhao Z; Zhang Y
Ann Diagn Pathol; 2015 Aug; 19(4):232-8. PubMed ID: 26071054
[TBL] [Abstract][Full Text] [Related]
59. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
[TBL] [Abstract][Full Text] [Related]
60. Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival.
Chao C; Xu L; Silverberg MJ; Martínez-Maza O; Chen LH; Castor B; Abrams DI; Zha HD; Haque R; Said J
AIDS; 2015 Sep; 29(15):1943-51. PubMed ID: 26355571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
